Related Experiment Video
Updated: Jun 26, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Bortezomib in Patients Who Fail BTKi in Waldenström Macroglobulinaemia
Jahanzaib Khwaja1, Nicole Japzon1, Simona Gatto2
1Department of Haematology, University College London Hospital, London NW1 2BU, UK.
Abstract:
Background: Treatment options after Bruton's tyrosine kinase inhibitors (BTKi) failure in Waldenstrom macroglobulinaemia are limited. Methods: We retrospectively analysed the use of bortezomib after BTKi failure in 17 patients who were heavily pre-treated and chemotherapy-exposed at our centre between 2018 and 2025. Results: Reasons for BTKi failure were disease progression (59%) and intolerance (41%). At bortezomib initiation, the median age was 73 years and two patients experienced grade 1-2 neuropathy. The best overall response rate (ORR) was 88%. At a median follow up of 39 months (interquartile range 35-78), median treatment-free survival and overall survival were 18 (95% confidence interval [CI] 13-22) and 22 (95% CI 17-45) months, respectively. Conclusion: Bortezomib may be efficacious in patients who experience BTKi failure.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...